Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5695365 | 0.99 | HTR2A (0.41) | HTR2ASLC6A2HTR2CSLC6A4TRPV1 | |
| Bromide SCHEMBL5695364 | 0.99 | HTR2A (0.41) | HTR2ASLC6A2HTR2CSLC6A4TRPV1 | |
| SCHEMBL1708540 | 0.78 | SLC6A2 (0.47) | HTR2ASLC6A2HTR2CSLC6A4TRPV1 | |
| SCHEMBL13494346 | 0.78 | HTR2A (0.47) | HTR2ASLC6A2HTR2CSLC6A4TRPV1 | |
| Bromide SCHEMBL13835350 | 0.74 | HTR2A (0.44) | HTR2ASLC6A2SLC6A4KDM1AMAOB | |
| SCHEMBL1707363 | 0.69 | SLC6A4 (0.39) | HTR2ASLC6A2HTR2CSLC6A4TRPV1 | |
| SCHEMBL16473204 | 0.67 | HTR2A (0.38) | HTR2ASLC6A2HTR2CSLC6A4PGR | |
| SCHEMBL15617162 | 0.67 | TDP1 (0.41) | HTR2ASLC6A2HTR2CSLC6A4PGR | |
| SCHEMBL10690532 | 0.65 | CYP19A1 (0.50) | — | |
| SCHEMBL9448056 | 0.64 | STS (0.39) | TRPV1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901310-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901310-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2307375-B1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | PFIZER (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8552035-B2 | Phenanthrenone compounds, compositions and methods | PFIZER INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8445520-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445520-B2 | Tricyclic compounds, compositions, and methods | PFIZER INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120157502-A1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157502-A1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095062-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS | PFIZER INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095062-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS | PFIZER INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7598231-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598231-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7547714-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease | PFIZER, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547714-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease | PFIZER, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | PFIZER, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | PFIZER, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008093227-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | PFIZER, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093236-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188443-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression | NR3C1, NR3C2, MC2R | HTR2A 298/4885SLC6A2 1717/4885HTR2C 122/4885 |
| US-20120095062-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS | NR3C2, NR3C1, MC2R | HTR2A 673/4885SLC6A2 815/4885HTR2C 292/4885 |
| US-20120157502-A1 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS | NR3C2, NR3C1, MC2R | HTR2A 563/4885SLC6A2 531/4885HTR2C 315/4885 |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | NR3C1, NR3C2, MC2R | HTR2A 371/4885SLC6A2 1204/4885HTR2C 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.